New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 9, 2012
Today's noteworthy initiations include: ARIAD (ARIA) initiated with a Buy at Guggenheim... Abiomed (ABMD) initiated with a Market Perform at Raymond James... Alexion (ALXN) initiated with a Buy at Guggenheim... Amgen (AMGN) initiated with a Neutral at Guggenheim... Biogen (BIIB) initiated with a Neutral at Guggenheim... Celgene (CELG) initiated with a Buy at Guggenheim... Cubist (CBST) initiated with a Neutral at Mizuho... Forest Labs (FRX) initiated with a Buy at Mizuho... Gilead (GILD) initiated with a Buy at Guggenheim... Infineon (IFNNY) initiated with an Outperform at Bernstein... Palo Alto (PANW) initiated with a Neutral at BofA/Merrill... PrivateBancorp (PVTB) initiated with a Market Perform at Wells Fargo... Volcano (VOLC) initiated with an Outperform at Raymond James... WPX Energy (WPX) initiated with a Hold at Deutsche Bank... Zale (ZLC) initiated with a Buy at Citigroup.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
November 22, 2015
13:21 EDTCELGAlphabet, Celgene, others could rise 20% over next year, Barron's says
Subscribe for More Information
November 20, 2015
15:22 EDTPANWPalo Alto volatility elevated into Q1 and outlook
Subscribe for More Information
10:52 EDTCELGFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information
09:44 EDTWPXAres EIF Group completes $185M Van Hook Gathering System acquisition
Ares Management (ARES) announced that a fund managed by its Ares EIF group has completed its acquisition of the Van Hook Gathering System in North Dakota from WPX Energy (WPX) in a transaction valued at $185M. The transaction was originally announced on August 31, 2015. The acquisition consists of pipeline systems that currently gather approximately 11,000 barrels of oil, 6,500 million cubic feet of natural gas, and 5,000 barrels of water per day from WPX Energy's Bakken shale oil assets. WPX Energy will continue to operate the Van Hook Gathering System, and MCP Operating, LLC, a subsidiary of MCP Asset Development Group, will provide asset management services for the investment.
07:17 EDTBIIBBiogen says Benepali receives 'positive' opinion from CHMP
Subscribe for More Information
November 19, 2015
16:06 EDTAMGNAmgen's Kyprolis approved for multuple myeloma by European commission
Amgen announced the European Commission granted marketing authorization for Kyprolis in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The EC approved Kyprolis based on data from the pivotal Phase 3 ASPIRE trial. The study showed that patients treated with Kyprolis in combination with lenalidomide and dexamethasone had increased median time to progressive disease or death by 8.7 months compared to patients treated with lenalidomide and dexamethasone. Approval from the EC grants a centralized marketing authorization with unified labeling in the 28 countries that are members of the EU. Norway, Iceland and Liechtenstein, as members of the European Economic Area, will take corresponding decisions on the basis of the decision of the EC. Amgen plans to submit data from the Phase 3 ENDEAVOR trial for potential authorization of Kyprolis in combination with dexamethasone in the EU. This data also serves as the basis of the supplemental New Drug Application of Kyprolis in combination with dexamethasone for patients with relapsed multiple myeloma, which has been accepted for priority review by the FDA.
07:15 EDTPANWPalo Alto Fortinet seen as potential Cisco takeover targets, says Oppenheimer
Subscribe for More Information
November 18, 2015
09:34 EDTGILDActive equity options trading on open
Subscribe for More Information
November 17, 2015
10:47 EDTGILDBristol-Myers strength attributed to sale chatter
The move higher in shares of Bristol-Myers (BMY) is being attributed by traders to chatter of a sale. The stock is up 2%, or $1.06, to $66.08 in morning trading. The unconfirmed talk has the company possibly approaching Gilead (GILD) about buyout interest. Bristol's market capitalization is just above $110B while Gilead's is just above $150B. Shares of Gilead are up 74c to $104.55.
08:54 EDTIFNNYMaxim could be bidder for Fairchild, says Citi
Citi analyst Atif Malik views Maxim Integrated (MXIM) as a potential acquirer Fairchild Semiconductor (FCS). Bloomberg on October 13 reported that Fairchild was seeking advice for a potential sale, and listed potential acquirers as STMicroelectronics (STM), Infineon (IFNNY) and ON Semiconductor (ON). Bids from STM and ON seem unlikely, but Infineon and Maxim could be potential acquirers of Fairchild, Malik tells investors in a research note. In a bull case scenario, Fairchild's buyout value could reach $25 per share, the analyst contends. Fairchild closed yesterday at $17.76. Malik's peer at Citi, analyst Christopher Danely, argued today in research note that Maxim Integrated (MXIM) is unlikely to get acquired despite reports of interest from Analog Devices (ADI) and Texas Instruments (TXN). Danely views Xilinx (XLNX) as a potential takeout target, potentially for Qualcomm (QCOM).
08:22 EDTCELGSignificant Celgene overhang removed, says JMP Securities
Subscribe for More Information
08:05 EDTPANWPalo Alto volatility elevated into Q1 and outlook
Palo Alto November call option implied volatility is at 43, November weekly is at 69, December is at 54, January is at 46; compared to its 52-week range of 27 to 66, suggesting large near term price movement into the expected release of Q1 results on November 23.
07:42 EDTPANWPalo Alto checks point to above-consensus Q1 results, says Stephens
Subscribe for More Information
07:37 EDTPANWPalo Alto results should beat expectations, says RBC Capital
Subscribe for More Information
November 16, 2015
16:05 EDTAMGNAmgen to present eight IMLYGIC abstracts
Subscribe for More Information
13:11 EDTCELGCelgene jumps 2% after defeating Kyle Bass patent challenge
Shares of Celgene moved higher after the U.S. Patent and Trademark Office declined to review a Revlimid patent expiring in 2019. The USPTO found that that Bass's Coalition for Affordable Drugs was unlikely to succeed, according to Bloomberg. Shares of Celgene are up 2%, or $1.64, to $190.13 in afternoon trading. The agency is reviewing two other patents on the drug.
13:08 EDTCELGCelgene defeats Bass challenege on Revlimid patent, Bloomberg reports
Subscribe for More Information
09:04 EDTGILDGilead says Phase 3 Zydelig study shows 'clinical benefit'
Gilead announced that its Phase 3 Study 115 evaluating Zydelig added to standard therapy in previously-treated chronic lymphocytic leukemia patients will be unblinded early. The DMC recommendation is based upon a predefined interim analysis indicating a statistically significant benefit in efficacy for progression-free survival and overall survival in patients receiving Zydelig plus bendamustine and rituximab, compared to those receiving only bendamustine and rituximab. The safety profile of Zydelig was consistent with prior studies. Detailed results from this study will be presented during a late-breaking abstracts session at the Annual Meeting of the American Society of Hematology in Orlando, Florida taking place December 5-8. "The clinical benefit observed in this Phase 3 study adds to the body of evidence demonstrating the potential of Zydelig-containing treatment regimens for patients with previously treated CLL," said Norbert W. Bischofberger, PhD, Gilead's Executive Vice President, Research and Development and Chief Scientific Officer. "We look forward to sharing the detailed scientific data with the hematology community at the upcoming ASH meeting."
November 15, 2015
20:17 EDTGILDGilead presents results from four Phase 3 studies of sofosbuvir/velpatasvir
Subscribe for More Information
15:47 EDTGILDGilead reports data from multiple studies of Viread, TAF, others
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use